A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg everolimus tablets suspended in 30 mL of water to healthy subjects

Trial Profile

A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg everolimus tablets suspended in 30 mL of water to healthy subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Angiomyolipoma; Astrocytoma; Bladder cancer; Breast cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Endometrial hyperplasia; Glioma; Head and neck cancer; Hepatocellular carcinoma; Hodgkin's disease; Multiple myeloma; Neuroendocrine tumours; Neurofibromatosis 2; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Plexiform neurofibroma; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Tuberous sclerosis
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 19 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top